Characteristic Of The Morphometric Parameters Of The Liver In Polypragmasia
Keywords:
Abstract
We have studied the morphological, morphometric parameters of the liver of white rats. Against the background of polypharmacy, when using non-steroidal anti-inflammatory drugs, it was revealed in the structure of the liver, which led to various damage to the liver parenchyma. The simultaneous use of non-steroidal anti-inflammatory drugs leads to acute or chronic liver failure in rats. The longer the therapy for chronic diseases, the more pronounced morphological changes (necrosis, fibrosis, and cholestasis).
Similar Articles
-
Clinical And Epidemiological Assessment And Causes Of Mortality From COVID-19 Coronavirus Infection (Literature Review)
The American Journal of Medical Sciences and Pharmaceutical Research: No. 09 (2021) / Haitov Abdulaziz Haydar O'g'li, -
Dangerous Symptoms Of Covid-19 Virus And Analysis Of Their Characteristics
The American Journal of Medical Sciences and Pharmaceutical Research: No. 10 (2021) / A.B. Tleubergenova , Z.U. Kunnazarova, -
Clinical And Epidemiological Aspects Of A New Coronavirus Infection (Covid-19)
The American Journal of Medical Sciences and Pharmaceutical Research: No. 09 (2021) / Bayramgul Sadykovna Jumamuratova, -
CHARACTERISTICS OF INTESTINAL MICROBIOTSENOSIS IN COVID-19 PATIENTS
The American Journal of Medical Sciences and Pharmaceutical Research: No. 04 (2022) / Aminjon Ne'matov , Islambek Kudiyarov, Nodira Yodgorova, Zuxra Orinbayeva, -
Role Of The PCSF Scale For Patients With Postcovid Syndrome
The American Journal of Medical Sciences and Pharmaceutical Research: No. 7 (2021) / Daminov B.T., Muminov D.K., Davron Kadirovich Muminov, -
The State Of The Cardiovascular System In Patients With Covid-19 In The Early Rehabilitation Period
The American Journal of Medical Sciences and Pharmaceutical Research: No. 7 (2021) / Daminova L.T., Daminov B. T., Muminov D.K., Davron Kadirovich Muminov, -
The Course Of Chronic Liver Disease In Patients With Covid-2019 (Literature Review And Own Data)
-
Improving The Organization Of Nursing Care In Treatment And Prevention Facilities For Patients With Covid-19
The American Journal of Medical Sciences and Pharmaceutical Research: No. 01 (2021) / M.R Salimova , G.K Khudoykulova, N.I Mamiraliyev , -
COMPARATIVE ANALYSIS OF THE FREQUENCY OF RS1801133 POLYMORPHISM OF THE MTHFR GENE IN THE GROUP OF PATIENTS WITH POSTCOVID COMPLICATIONS OF MAXILLOFACIAL AREA
The American Journal of Medical Sciences and Pharmaceutical Research: No. 01 (2022) / Sh.A. Boymuradov, Y.Kh. Kurbonov, J.A.Djuraev, -
Risk Of Pulmonary Artery Thrombosis In Type 2 DM Patients Hospitalized With Covid-19
The American Journal of Medical Sciences and Pharmaceutical Research: No. 08 (2021) / Nodirbek Ilkhomjon Ogli Yakubov, Dilfuzahon Zakirjanovna Mamarasulova, Nataliya Gamletovna Dadamyants, Anvar Arabbayevich Dalimov,
References
Baykova I.E., Nikitin I.G. (2009) Medicinal liver damage. RMJ (Russian Medical Journal), 1. pp. 4-10.
Bueverov A.O. (2009) Possibilities of treating drug-induced liver damage in conditions of the need to continue taking hepatotoxic drugs. Treat. physician, 2. Pp. 3-8.
Zvyagintseva T.D., Chernobay A.I. (2011) Medicinal hepatitis: from pathogenesis to treatment. Medicine and Pharmacy News, 375. pp. 23-28.
Zvyagintseva T.D., Chernobay A.I. (2011) Basic principles of treatment of chronic viral hepatitis. In the book: Chronic liver disease. Odessa, pp. 109-153
Zvyagintseva T.D., Chernobay A.I. (2006) Alcohol-viral liver damage: the effectiveness of the new complex hepatoprotector "PM Sirin". Semeina medicine, 2. Pp. 44–48.
Klyuchareva A.A. (2007) Medicinal hepatitis. Medical News, 14. Pp. 19-24.
Morozov Yu.A., Kucheryavyy Yu.A. (2011) Hepatoprotectors in clinical practice: rational aspects of use. A guide for doctors. 4TE Art., Moscow, p. 28.
Polunina T.E. (2013) Management of patients with drug-induced liver damage. Difficult Patient, 4. Pp. 8-13.
Kharchenko N.V., Anokhina G.A., Kharchenko V.V. (2013) Complex multifunctional hepatoprotectors in the treatment of patients with non-alcoholic liver disease in combination with hypertension. Practicing Likar, 1. Pp. 64-66.
Shirokova E.N. (2012) Medicinal lesions of the liver. Lecture at the All-Russian Internet Congress of Specialists in Internal Medicine. (internist.ruhttp: //www.internist.ru/articles/vnutrennie/vnutrennie_671.html).
Shuba N.M., Voronova T.D. (2009) NSAID hepatotoxicity: is there a real threat? Ukr. rheumatol. zhurn., 1 (35). Pp. 33–39.
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., ... & Daly, A. K. (2011). Case definition and phenotype standardization in drug‐induced liver injury. Clinical Pharmacology & Therapeutics, 89(6), 806-815.
Banks A., Zimmerman H., Isshak K., Harter J.G. (1995) Diclofenak-associated hepatotoxicity: an analysis of 180 cases report to the Food and Drug Administration as adverse reactions. Hepatology. 22 (3). Pp. 820-870.
Bell, L. N., & Chalasani, N. (2009, November). Epidemiology of idiosyncratic drug-induced liver injury. In Seminars in liver disease (Vol. 29, No. 04, pp. 337-347). © Thieme Medical Publishers.
Bhogaraju, A., Nazeer, S., Al-Baghdadi, Y., Rahman, M., Wrestler, F., & Patel, N. (1999). Diclofenac-associated hepatitis. Southern medical journal, 92(7), 711-713.
Leitner, J. M., Graninger, W., & Thalhammer, F. (2010). Hepatotoxicity of antibacterials: pathomechanisms and clinical data. Infection, 38(1), 3-11.
Galati, G., Tafazoli, S., Sabzevari, O., Chan, T. S., & O'Brien, P. J. (2002). Idiosyncratic NSAID drug induced oxidative stress. Chemico-biological interactions, 142(1-2), 25-41.
Hughes, B. (2008). Industry concern over EU hepatotoxicity guidance. Nature Reviews Drug Discovery, 7(9), 719.
Leitner J. M., Graninger W., Thalhammer Infection., 38 (1). pp. 3-11.
Marschall H. U., Wagner M., Zollner G., Trauner M. (2007) Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol. pharm. 4 (6): 895-910.
